Information Provided By: 
Fly News Breaks for December 13, 2019
SRPT
Dec 13, 2019 | 06:46 EDT
RBC Capital analyst Brian Abrahams raised his price target on Sarepta to $215 and kept his Outperform rating after FDA announced the approval of Vynodys 53 injection to treat DMD, saying the decision is a "big win" for the company, giving it a "second market product" and a "a foundation of revenues" for its gene therapy offerings. The analyst adds that the event marks the FDA flexibility in expediting new DMD drugs considering the prior rejection of Vynodys.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
